Novo Nordisk

CompanyDenmark

Novo Nordisk develops 10 assets, the furthest approved (estradiol in atrophic vaginitis). Mostly peptide and small molecule acting on inflammation, Insulin/IGF-1 signalling and lipid and ceramide metabolism; based in Denmark.

Assets
10
Furthest
Approved
Grants
1
Trials
422
Signals
10

Pipeline

10

7 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms11
  • Trials503
  • Signals20
  • Integrity notices2
  • Similar companies6

Papers

Updated 7 Oct 2026 · 296 sources

Intelligence